Juvenile myelomonocytic leukemia.

Area of Science:

• Pediatric Hematology Oncology
• Molecular Genetics
• Cancer Biology

Background:

• Juvenile myelomonocytic leukemia (JMML) is a rare childhood neoplasm.
• It presents with splenomegaly, hepatomegaly, and peripheral blood abnormalities like leukocytosis and monocytosis.
• Bone marrow shows myelomonocytic proliferation and often reduced megakaryocytes.

Purpose of the Study:

• To describe the key features of JMML.
• To highlight the characteristic hypersensitivity of marrow progenitors to GM-CSF.
• To discuss the underlying molecular mechanisms and therapeutic challenges.

Main Methods:

• Clinical presentation and peripheral blood/bone marrow findings review.
• In vitro assessment of progenitor cell hypersensitivity to GM-CSF.
• Molecular analysis of RAS-signaling pathway components.

Main Results:

• JMML exhibits features of both myelodysplastic and myeloproliferative disorders.
• Hallmark finding is in vitro hypersensitivity of marrow progenitors to GM-CSF.
• Aberrant RAS-signaling pathway mutations are identified as drivers of proliferation.

Conclusions:

• JMML is an aggressive childhood cancer driven by specific molecular alterations.
• Hematopoietic stem cell transplantation is the only curative option.
• High relapse rates post-transplant necessitate further research into novel therapeutic strategies.